Table 2. Patient characteristics, details of therapy and timing of bone marrow and peripheral blood sampling in group III patients.
| Patient no. | Date of diagnosis | Tumour type | Size (mm) | Grade | No. of LN | ER status | PR status | Therapy during study | Time from diagnosis BM1 (months) | QPCR | ICC | Time from diagnosis BM2 (months) | QPCR | ICC | Time from diagnosis PB1 (months) | CTCs | Time from diagnosis PB2 (months) | CTCs | Time from diagnosis PB3 (months) | CTCs | Time from diagnosis PB4 (months) | CTCs | Time from diagnosis PB5 (months) | CTCs | Time from diagnosis PB6 (months) | CTCs | Time from diagnosis PB7 (months) | CTCs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 09/01/1999 | IDC | 30 | 3 | 4\13 | 3+ | — | Arim | 78 | 0.12 | 0 | 84 | 0.25 | 2 | 77 | 2 | ND | 99 | 0 | ND | 105 | 0 | 108 | 0 | 111 | 1 | ||
| 20 | 09/01/1995 | IDC | 30 | 3 | 12\17 | 1+ | 1+ | Nil | 126 | 0.18 | 1 | 132 | 0.11 | 1 | 125 | 0 | 132 | 0 | 149 | 0 | 152 | 1 | 156 | 2 | 159 | 0 | ||
| 21 | 07/01/1994 | ILC | >50 | 3 | 12\16 | — | — | Nil | 137 | 0.10 | 0 | 143 | 0.47 | 7 | 135 | 5 | 140 | 0 | 162 | 0 | 165 | 0 | 167 | 1 | 170 | 0 | ||
| 22 | 05/01/1997 | IDC | 27 | 3 | 6\19 | Neg | Neg | Nil | 102 | 0.22 | 3 | 108 | 0.08 | 0 | 102 | 1 | 108 | 0 | 125 | 1 | 128 | 1 | ND | 134 | 0 | |||
| 23 | 01/01/1996 | IDC | 33 | 3 | 4\20 | — | — | Nil | 117 | 0.03 | 0 | 123 | 0.00 | 0 | 119 | 0 | 125 | 0 | 138 | 0 | 141 | 1 | 144 | 0 | 147 | 0 | ||
| 24 | 09/01/1996 | ILC | 55 | 2 | 5\29 | 3+ | 2+ | Nil | 129 | 0.02 | 1 | 135 | 0.10 | 1 | 119 | 0 | 124 | 0 | 138 | 0 | 142 | 0 | ND | 148 | 0 | |||
| 25 | 23/12/1997 | Tubular | 11 | - | 2\13 | Pos | Pos | Tam | 113 | 0 | 117 | 0 | 121 | 0 | 123 | 0 | ||||||||||||
| 26 | 12/03/1997 | IDC | 16 | 2 | 16\36 | 1+ | 1+ | Arim | 92 | 0.14 | 0 | 104 | 0.00 | 0 | 98 | 0 | 100 | 0 | 122 | 0 | 126 | 0 | 129 | 0 | 132 | 0 | ||
| 27 | 08/01/1999 | IDC | 10 | 2 | 5\15 | 3+ | 3+ | Arim | 68 | 0.22 | 1 | 74 | 0.04 | 0 | 76 | 0 | 82 | 0 | 100 | 0 | 104 | 0 | 107 | 0 | 112 | 0 | ||
| 28 | 01/01/1997 | IDC | 20 | 3 | 8\21 | Neg | Neg | Nil | 107 | 0.20 | 3 | 113 | 0.20 | 0 | 106 | 0 | 112 | 2 | Relapsed with metastatic disease 115 months after diagnosis | |||||||||
| 29 | 11/01/1998 | IDC | 30 | 3 | 6\18 | Neg | Neg | Nil | 78 | 0.12 | 1 | 84 | 0.20 | 1 | 84 | 0 | 90 | 0 | ||||||||||
| 30 | 02/01/2000 | IDC | 13 | 3 | 9\21 | Pos | Neg | Arim | 70 | 0.18 | 1 | 76 | 0.32 | 0 | ND | 76 | 0 | 89 | 0 | 92 | 0 | 94 | 1 | 97 | 0 | 100 | 0 | |
| 31 | 05/01/1998 | IDC | 25 | 3 | 6\11 | Pos | — | Nil | 91 | 0.03 | 6 | 97 | 0.09 | 0 | 91 | 0 | ND | 113 | 0 | 116 | 0 | 119 | 0 | 121 | 0 | 124 | 1 | |
| 32 | 03/01/1997 | IDC | 60 | 3 | 4\31 | Neg | Neg | Nil | 104 | 0.03 | 0 | 110 | 0.52 | 1 | 104 | 0 | 110 | 0 | 125 | 1 | 128 | 0 | 131 | 0 | 133 | 0 | ||
| 33 | 27/09/1994 | IDC | 23 | 3 | 9\29 | — | — | Nil | 151 | 0 | 154 | 2 | 157 | 0 | 161 | 0 | 164 | 0 | ||||||||||
| 34 | 03/01/1995 | Both IDC | 2 × 16 and 22 | 3 | 9\24 | 1+ | 1+ | Nil | 126 | 0.06 | 0 | 132 | 0.13 | 3 | 132 | 8 | 136 | 0 | ||||||||||
| 35 | 05/01/1997 | IDC | 50 | 3 | 4\22 | Neg | Neg | Nil | 95 | 0.02 | 0 | 101 | 0.00 | 0 | 95 | 0 | 101 | 0 | 125 | 0 | ND | ND | 132 | 0 | ||||
| 36 | 09/01/1997 | T2 N1 | 25 | 2 | 11\20 | 2+ | 2+ | Nil | 90 | 0.06 | 0 | 96 | 0.06 | 1 | 96 | 0 | 109 | 0 | 124 | 0 | 127 | 0 | 130 | 1 | 133 | 1 | 136 | 0 |
| 37 | 10/01/1995 | ILC | 35 | 2 | 9\21 | — | — | Nil | 122 | 0.01 | 0 | 128 | 0.07 | 0 | 123 | 0 | 127 | 0 | 149 | 0 | 152 | 0 | ND | |||||
| 38 | 06/01/1999 | IDC plus DCIS | 25 | 3 | 4\29 | 2+ | 2+ | Arim | 78 | 0.01 | 0 | 84 | 0.05 | 0 | 78 | 0 | 84 | 0 | 100 | 1 | 103 | 1 | 107 | 23 | 112 | 0 | ||
| 39 | 09/01/1997 | IDC | 40 | 3 | 10\21 | 1+ | 1+ | Nil | 93 | 0.02 | 1 | 99 | 0.00 | 0 | 99 | 0 | 103 | 0 | 126 | 1 | ND | 130 | 0 | 133 | 0 | |||
| 40 | 02/01/1999 | IDC | 45 | 3 | 6\14 | Pos | Pos | Arim | 84 | 0 | 0 | 90 | 0.13 | 0 | 84 | 0 | 90 | 0 | 105 | 0 | 108 | 1 | 111 | 0 | ||||
| 41 | 03/01/1998 | IDC | 40 | 2 | 7\27 | Pos | Pos | Arim | 94 | 0.07 | 0 | 100 | 0.07 | 0 | 93 | 0 | 100 | 0 | 115 | 0 | 118 | 0 | 120 | 0 | ||||
| 42 | 08/12/1997 | Multifocal IDC | >50 | 2 | 9\20 | 2+ | 3+ | Arim | 112 | 0 | 115 | 1 | 119 | 0 | 122 | 1 | 125 | 2 | ||||||||||
| 43 | 09/01/1997 | TX N4 | — | 3 | 14\25 | Neg | Neg | Nil | 95 | 0.04 | 1 | 101 | 0.03 | 0 | 101 | 1 | 105 | 0 | ||||||||||
| 44 | 04/01/1998 | IDC | 60 | 2 | 8\19 | — | — | Tam | 74 | 0.11 | 0 | 86 | 0.23 | 1 | ND | 96 | 7 | Relapsed with metastatic disease 101 months after diagnosis | ||||||||||
| 45 | 05/09/1995 | IDC | 18 | 2 | 8\13 | 2+ | Neg | Nil | 144 | 0 | 147 | 0 | 151 | 0 | ||||||||||||||
| 46 | 08/01/1997 | IDC | 20 | 2 | 7\19 | 3+ | 3+ | Nil | 85 | 0.12 | 1 | 97 | 0.26 | 0 | 101 | 0 | 106 | 0 | 126 | 0 | 129 | 1 | 132 | 0 | 135 | 0 | ||
| 47 | 29/12/2003 | IDC | 15 | 3 | 45\45 | Neg | Neg | CT (FEC) | 41 | 0 | 44 | 0 | ND | 49 | 0 | 53 | 0 | |||||||||||
| 48 | 16/12/1998 | Mucoid carcinoma | 50 | 1 | 8\19 | 2+ | 3+ | Arim | 72 | 0.03 | 0 | 84 | 0.05 | 0 | 84 | 3 | 97 | 0 | 103 | 0 | 106 | 0 | 109 | 1 | 112 | 0 | ||
| 49 | 08/01/1999 | IDC | 20 | 3 | 4\26 | Neg | Neg | Nil | 61 | 0.33 | 2 | 72 | 0.53 | 0 | 77 | 1 | 83 | 0 | 99 | 1 | ND | 105 | 0 | 108 | 0 | 111 | 0 | |
| 50 | 02/01/2001 | IDC | 14 | 2 | 20\39 | 3+ | 3+ | Arim | 49 | 0.00 | 0 | ND | ND | 61 | 0 | 65 | 0 | 77 | 1 | 81 | 1 | 84 | 0 | 88 | 1 | |||
| 51 | 01/01/2000 | Multifocal lobular carcinoma | 17 | 3 | 6\18 | 3+ | 3+ | Arim | 37 | 0.08 | 1 | 51 | 0.03 | 0 | 47 | 0 | 51 | 0 | 87 | 0 | 90 | 0 | 93 | 0 | 97 | 0 | 100 | 1 |
Arim=arimidex; BM=bone marrow; CT=chemotherapy; CTCs=circulating tumour cells; DCIS=ductal carcinoma in situ; DTCs=disseminated bone marrow tumour cells; ER=oestrogen receptor; FEC=fluorouracil, epirubicin and cyclophosphamide; ICC=immunocytochemistry; IDC=infiltrating ductal carcinoma; ILC=infiltrating lobular carcinoma; ND=not done; Neg=negative; PB=peripheral blood; Pos=positive; PR=progesterone receptor; QPCR=quantitative PCR; Tam=tamoxifen.
High-risk patients therapy and monitoring details.
Results for CTCs and DTCs in 33 group III high-risk primary breast cancer patients.